Navigation

Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov/.

Updates regarding government operating status and resumption of normal operations can be found at https://USA.gov/.

You are here: Home / Protocols / Targeted Sequencing for Discovery and Validation of DNA Methylation Markers of Colon Cancer Metastasis
Team Project

Targeted Sequencing for Discovery and Validation of DNA Methylation Markers of Colon Cancer Metastasis

363

No coordinating investigator defined.

Genomics
G.I. and Other Associated Cancers Research Group

Colon cancer is the second leading cause of cancer death in the United States. A key issue in treating colon cancer patients is inability to accurately predict tumors that have metastatic potential and require adjuvant chemotherapy. This project will test the model that tumor metastases arise from intra-tumor heterogeneity generated by DNA methylation events, and that detecting these events can provide a predictve signature of tumors with poor outcome

The specific aims of this study are to determine whether in human colon cancer epigenetic gene silencing by aberrant DNA methylation provides the basis for intra-tumor heterogeneity and generation of lethal metastasis. We will answer this question by: 2.1. Comprehensive NextGeneration sequencing based analysis of DNA methylation across promoter associated CpG islands will be used to compare the DNA methylome of 20 colon cancer hepatic metastases versus 20 matched primary colon cancer tumors. 2.2. Sequence comparisons of the DNA methylome between matched colon cancer hepatic metastases and colon cancer primary tumors will be analyzed to identify presence or absence of metastases specific DNA methylation signatures, and to determine whether metastases are clonally identical to colon cancer primaries, are generated from subclones within colon cancer primaries, or are generated from subclones that arise in blood or distant sites outside of colon cancer primaries. Methyl-BEAMing based assays will be used to confirm the presence or absence within colon cancer primaries of subclones bearing DNA methylation signatures that typify the metastatic lesions, but are divergent from the dominant signature of tumor primaries. 2.3. The predictive potential of metastases associated methylation marks will be tested by determining the frequency of these aberrant methylation marks in a validation cohort of over 700 colon cancer tissue specimens from early stage colon cancer primaries, late stage colon cancer primaries, and colon cancer hepatic metastases.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

10th Science Workshop
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. Click to view the flyer; click to visit the registration page.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.